Aerosol BCG treatment of carcinoma metastatic to the lung: a phase I study.
BCG (TICE) was safely administered to 15 patients with metastatic cancer to the lungs in weekly doses of up to 3 X 107 organisms by the aerosol route. The aerosol route of administration is associated in approximately 33% of the doses with a toxicity syndrome of malaise, fever, and chills beginning 4 to 8 hours after treatment and ending within 24-36 hours. This syndrome is experienced by all patients and symptoms gradually subside with continuation of therapy. No hepatic or pulmonary toxicity was documented during the 221 treatment doses.
D000336:Aerosols; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005334:Fever / Q000209:etiology; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D008175:Lung Neoplasms / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D009362:Neoplasm Metastasis; D012882:Skin Tests; D013997:Time Factors; D014797:Vital Capacity
D000336:Aerosols; D001500:BCG Vaccine